Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
ES

OTC · ESLOY

EssilorLuxottica S.A.

Healthcare · Medical - Instruments & Supplies

$102.66

Up+$2.86 (+2.87%)

Updated Oct 31, 2026, 6:07 PM

SID Score

4.6/10

Composite research score

Smart Money

46/100

Neutral

Market cap
152.72B
P/E ratio
54.42
Dividend yield
2.20%
52-week range
$79.27 – $186.81
Volume
206.72K
Avg. volume
53.93K

Price performance · ESLOY

ESLOY price history

1M range · 6 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

ESLOY closed at $82.26 after 6 trading sessions, up 2.00% for the selected period.

Last close
$82.26
Period change
+2.00%
Period low
$80.65
Period high
$82.26
Daily close
View OHLC price history
ESLOY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$82.13$82.596$81.295$82.26206.72K
Oct 8, 2026$80.73$80.93$79.845$80.87126.39K
Oct 7, 2026$81.73$82.17$81.12$82.17170.95K
Oct 6, 2026$81.72$82.79$81.4175$82.03198.15K
Oct 5, 2026$80.86$81.49$80.59$81.44213.11K
Oct 2, 2026$82.15$82.158$80.24$80.65131.23K

Latest ESLOY news

The latest Smart Investors Daily articles mentioning ESLOY.

Stock researchCompany · Overview

ESLOY research

Overview

Company profile and research snapshot.

Company profile

ESSILOR LXTTCA UNSP/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
—
Implied upside
—
Analysts
12
ESLOY recent ratings
DateFirmRatingTarget
Sep 23, 2026LANDESBANK BADEN-WUERTTEMBERGBuy—
Sep 21, 2026DAY BY DAYSell—
Sep 21, 2026EQUITA SIMBuy—
Sep 18, 2026STIFEL EUROPEBuy—
Sep 15, 2026JEFFERIESBuy—
Open full forecast

News briefing

Generated Oct 31, 2026, 5:05 PM

Why Is ESLOY Up Today?

EssilorLuxottica shares gained 2.87% today, driven by positive investor sentiment around the eyewear and luxury goods conglomerate amid renewed market attention. The stock's strength reflects growing interest in Eurozone healthcare and consumer discretionary plays, though recent family governance developments add complexity to the investment narrative.

    Bottom line: ESLOY's 2.87% gain reflects renewed investor interest in the luxury eyewear leader as part of a broader Eurozone healthcare recovery theme. While the company's market positioning, brand strength, and margin profile remain structurally sound, ongoing family governance tensions around stake ownership create near-term uncertainty that investors should monitor closely. Watch for any announcements regarding the Wertheimer family negotiations and upcoming earnings guidance.

    Yahoo · Oct 30, 2026

    EssilorLuxottica Stock And Eurozone Healthcare Giants Worth Watching Now

    Eurozone growth just cooled to 0.4% in Q3, yet still beat forecasts, and that mix of resilience and slowdown is quietly reshaping where money could flow next. Some businesses may benefit if investors rethink how far the ECB can cut, while others face pressure from weaker France and Germany. This article walks through three large cap eurozone stocks exposed to these cross-currents and why their reactions to the news deserve a closer look now. The three stocks below are just a sample of this...

    Yahoo · Oct 23, 2026

    S&P upgrades EssilorLuxottica to ’A+’ on strength of medtech pivot

    Investing.com -- S&P Global Ratings has upgraded EssilorLuxottica SA's (EPA:ESLX) long-term issuer credit rating to ‘A+’ from ‘A’, citing the company's successful pivot from a traditional consumer goods business into an integrated medtech leader. The rating agency affirmed the group's 'A-1' short-term rating while assigning a stable outlook, reflecting expectations that core vision care demand will continue to shield the group from broader macroeconomic headwinds.

    AI research layers

    Interpretive context generated from the platform’s current data sources.

    No results

    AI research layers have not been published yet.

    Featured By